New Hungary Pharma Report 2020 Out Now
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
The Hungarian Investment Promotion Agency (HIPA) was established under a Government Decree to provide professional help to foreign companies intending to invest in Hungary. Our task is to support the implementation of the Government’s key investment promotion targets and to foster bilateral and multilateral international economic relations.
To this end, HIPA seeks and maintains contacts with potential foreign investors, helping them to prepare and implement strategic investment decisions, as well as providing post-decision support and encouraging their intention to re-invest. HIPA offers company and sector-specific consultancy, attends professional events, recommends locations, and organizes site visits. HIPA also acts as a mediator between large international companies and Hungarian firms to facilitate supplier relationships, organizing supplier training, and maintaining active contact with trade associations, particularly in the automotive and electronics sectors.
Our ultimate goal is to see Hungarian SMEs play as large a role as possible in the local multinational supply chain. We cooperate with government bodies involved in promoting investment, taking a dynamic role in preparing government decisions supporting priority investment projects, and in drafting proposals for the external economic aid scheme.
HIPA also supplies company-specific subsidy information on Hungarian and EU co-financed programmes and manages the EKD programme (investments supported by individual government decisions).
Contact
Tel: +36 1 872 6520
Fax: +36 1 872 6699
E-mail: info@hipa.hu
Web: www.hipa.hu
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic…
See our Cookie Privacy Policy Here
